Medtronic makes concessions to European regulator in bid to close Covidien deal

Medtronic ($MDT) submitted unspecified concessions to the European Commission in a bid to close its $43 billion bid for Covidien ($COV) by early 2015. Overcoming antitrust concerns in various regions is one of the last impediments to the transaction. Last month, Covidien sold its clinical-stage drug-coated balloon to please antitrust authorities in the U.S. The European Commission will decide whether to approve the transaction by Nov. 28. News

Suggested Articles

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.

The dream of a comfortable, tabletop blood testing device, needing only a few drops taken from a finger and a handful of minutes, has now arrived.

Novartis is now teaming up with Amazon’s mammoth cloud computing division to overhaul its manufacturing, supply and business operations.